Amgen scouts for Boston R&D talent; Cambridge U-Phylogica create spinoff biotech;

@FierceBiotech: Sanofi puts European units on chopping block. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see some groups attack pharma for overstating R&D costs while investors demand to know why ROI is so bad for the industry. Follow @JohnCFierce

> Amgen's recent acquisition of BioVex is raising the Big Biotech's presence in beantown, according to the Boston Globe. And recruiters are out scouting for fresh talent for the company's discovery center on Kendall Square. Amgen's Roger Perlmutter says that he wouldn't be at all sorry to pick up top R&D players at Genzyme interested in pursuing a new career path now that Sanofi is stepping in. Says Perlmutter: "If they call us, we'll pick up the phone.'' Report

> Researchers at Cambridge University are joining hands with Phylogica to launch a spinoff company to pursue new uses of its peptide technology. Story

> Johnson & Johnson has scooped up nearly all of the shares of Crucell. Story

> Progenics Pharmaceuticals named Mark R. Baker chief executive officer. Prior to this promotion, Baker had served as president. Paul J. Maddon, M.D., Ph.D. has been appointed to the newly created position of vice chairman of the board of directors and will continue as chief science officer. Progenics release

> Ipsen announced that the FDA has approved its Prior Approval Supplement application for the Extended Dosing Interval of Somatuline Depot for patients suffering from acromegaly. Ipsen release

Pharma News

@FiercePharma: Sanofi's European revamp may kill 700 jobs. Story | Follow @FiercePharma

> J&J 'lied' about Risperdal's safety, S.C. lawyer alleges. Report

> Senators propose RICO-fueled crackdown on drug thefts. News

> Are pharma-doc links necessary or questionable? Article

Drug Delivery News

> FDA takes aim at some XR cold meds. News

> Alkermes's microsphere tech key to Bydureon. Story 

> SkyePharma stumbles after AstraZeneca decision on asthma drug. Item

> UPenn drug-delivery vector aims to avoid immune attacks. Article

> A crop of anti-pain meds rigged to thwart abuse. Report

Medical Device News

> J&J unit recalls potentially leaky insulin pump cartridges. Story 

> J&J's Cordis unit hit with warning letter on stents. Article 

> Medtronic opens regional HQ building in Shanghai. Report 

> Halma to buy Medicel for $75.5M. Item 

> Fenwal, Golden Meditech to form JV in China. News 

> NovaShunt raises $25M in Series B financing round. Story  

And Finally... A new survey of British adults say that the classic "seven-year itch" for relationships has now been cut down to a mere three years. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.